Navigation Links
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
Date:6/1/2009

ORLANDO - When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

The findings, presented today at the American Society of Clinical Oncology's annual meeting, mark the first clinical benefit of a small molecule targeted agent and standard chemotherapy in combination for lung cancer. Roy Herbst, M.D., Ph.D., professor and chief of the section of M. D. Anderson's Department of Thoracic/Head and Neck Medical Oncology, presented the findings on ASCO's press program.

"This study shows that an oral tyrosine kinase inhibitor can be combined with chemotherapy safely and effectively to provide systematic benefit to patients with this life-threatening disease," said Herbst. "This study will have immediate clinical implications. Still, we need to build on this research and turn our focus toward better identifying molecular markers involved, with the ultimate goal of personalizing our patient's care."

The therapy is unique in that it's a dual inhibitor and targets the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). It is the first single agent in lung cancer to target both receptors, said Herbst, the study's international principal investigator.

"Both receptors are active in lung cancer. EGFR targets the tumor cell and VEGF targets the blood vessels, so, with vandetanib, we're really targeting the entire tumor environment at the same time," explained Herbst. "As a dual inhibitor, it also may provide cost-savings to patients in that they can now potentially take one therapy instead of two."

According to the American Cancer Society, lung cancer accounts for the most cancer-related deaths. In 2009, 219,440 are expected to be diagnosed and 15
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
2. Vaccine shows therapeutic promise against advanced melanoma
3. Study shows gay couples want legal rights, regardless of marriage
4. Immune-Based Lymphoma Treatment Shows Promise
5. Avastin Shows No Benefit Against Early Stage Colon Cancer
6. Study shows drug combination improves outcome for advanced non-small cell lung cancer
7. Tool Shows Promise for Measuring Productivity of Mid-Level Oncology Providers
8. New Study Shows Probiotics Linked to Metabolism
9. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
10. Cottonseed-based drug shows promise in treating severe brain cancer
11. Dementia drugs may put some patients at risk, Queens study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
(Date:11/26/2014)... November 26, 2014 Louisiana Back ... and specialists in minimally invasive spine surgery, announces ... into the rapidly growing provider network of orthopedic ... addition coincides with the network’s continuing success providing ... for Louisiana residents who are suffering from orthopedic ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
(Date:11/26/2014)... Youngsters who enter puberty early are at increased risk ... was linked with a number of factors associated with ... according to the researchers. Early puberty was also linked ... peers, and having friends who were prone to getting ... found an association between early puberty and these factors, ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
(Date:11/26/2014)... News) -- Exposure to peanut protein in household dust ... with the skin condition eczema, a new study reveals. ... United States are allergic to peanuts. And severe eczema ... peanut allergy, the researchers noted. The new study ... The researchers examined the amount of peanut protein the ...
Breaking Medicine News(10 mins):Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2
... Volunteers trained on moveable platform kept better balance in ... -- Repeatedly exposing people to situations where the footing ... on slippery floors and avoid falls, says a University ... improves understanding of how the brain develops fall prevention ...
... Feb. 20 /PRNewswire-FirstCall/ -. Alsius Corporation,(Nasdaq: ... an agreement with a wholly-,owned subsidiary of ZOLL ... which Alsius,will sell to ZOLL substantially all the ... a purchase price of,$12 million in cash. ...
... Abbott ( NYSE: ABT ) today announced that it ... for its acquisition of Advanced Medical Optics (AMO) through ... common stock of AMO. The European Commission approved ... tender offer related to European Commission regulatory approval and ...
... China Healthcare Acquisition Corp. (the "Company") (NYSE ... Board of Directors has set March 5, 2009 as ... to receive liquidating distributions from the trust fund established ... public offering (the "IPO") and into which the net ...
... Feb. 20 Endo Pharmaceuticals (Nasdaq: ENDP ... announced today that the companies have settled litigation with ... of generic formulations of Opana(R) ER (oxymorphone hydrochloride) Extended ... to dismiss their suit with prejudice and Actavis has ...
... identify those at risk and tailor treatment methods , , FRIDAY, ... may explain why some people are more heavily dependent on ... Health System researchers linked the DNA sequencing of the SLC6A4 ... receiving help for alcohol dependency used to have. Serotonin, a ...
Cached Medicine News:Health News:Adapting Gait May Help Elderly Avoid Falls 2Health News:Alsius Corporation Announces Agreement to Sell Assets to ZOLL Medical Corporation 2Health News:Alsius Corporation Announces Agreement to Sell Assets to ZOLL Medical Corporation 3Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 3Health News:China Healthcare Acquisition Announces Record Date for Trust Fund Distribution 2Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 2Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 4Health News:Gene Variant Tied to Severity of Drinking 2
(Date:11/26/2014)... , Nov. 26, 2014 The medical ... a rate of 4%, with world market revenues ... Information. MRI and other types of medical imaging ... treatment of numerous medical conditions in children and ... techniques. Kalorama,s report, Medical Imaging Markets , ...
(Date:11/26/2014)... 25, 2014  At the American Dental Association,s Annual ... October, KaVo Kerr Group was honored to be part ... the opportunity to see and test the Best of ... deliver lectures on the latest developments in dental technology. ... new DEXIS CariVu Caries Detection Device and Kerr Demi ...
(Date:11/26/2014)...  Medtronic,s roughly $43 billion acquisition and ... in the media for its US Federal tax ... player in one of the fastest growing device ... research firm said  the two companies compete in ... of solutions spanning inpatient to home care, and ...
Breaking Medicine Technology:Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
... Plume-inator produces the strongest vacuum ... smoke evacuators. The unit ... hospital grade plug, footswitch, built-in ... purpose swing ring to hold ...
A system for the removal and filtration of laser and surgical smoke....
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PS Medical Strata valve is ... the resistance properties of the valve can ... is designed to minimize overdrainage of cerebrospinal ... within a normal physiologic range, regardless of ...
Medicine Products: